Join us this afternoon for Septerna’s #JPM25 podium presentation, in person or via webcast! We’re excited to share our progress in unlocking GPCR therapeutic potential for patient-focused treatments. #BiotechInnovation #GPCRScience

We’re thrilled to announce Gil Labrucherie has joined Septerna as Chief Financial Officer!. With 25+ years of senior leadership in biopharma and technology finance and legal roles, he will be instrumental as we advance SEP-786 and our GPCR pipeline. $SEPN

We’re thrilled to announce that Septerna is now publicly traded on NASDAQ under $SEPN! A huge thanks to our team, investors, and partners who made this moment possible. Here's to unlocking the potential of GPCR-targeted therapies. #GPCRScience #NASDAQ

At Septerna, we are committed to providing hope for new therapeutic options that can help patients meet their treatment goals. Learn more:

People living with Graves' disease face difficult choices with current treatments, often sacrificing one health goal for another. There is an urgent need for better treatment options that can address the challenges effectively. #GravesDiseaseAwarenessMonth.

We marked the month with events to foster understanding & promote allyship, & we look forward to joining Gay for Good SF for this weekend’s Pink Triangle Take-Down. #PrideMonth #Inclusion #LGBTQ #Pride2024.

Pride Month is a time to honor the past, celebrate progress, & advocate for greater inclusivity. We are committed to inclusion & equity for our talented LGBTQ+ employees & to developing therapies that improve patients' lives, many of whom are part of the LGBTQ+ community. 🏳️‍🌈

We are pleased to welcome our wonderful group of Summer interns, who will be working with us in medicinal chemistry, people and culture, protein science and platform technology. We look forward to seeing the valuable contributions they will make to our team.

We are also pleased to showcase data from our TSHR antagonist program demonstrating its ability to target the known drivers of Graves’ disease, an indication for which there are currently no disease-modifying oral small molecules.

CEO @Jeff Finer on the preclinical data we presented this week at #ENDO2024. Our PTH1R agonist is the only small molecule in development to behave similarly to native PTH. We’re excited about its potential to reshape the treatment of hypoparathyroidism.

Today at #ENDO2024 we presented preclinical data from our PTH1R and TSHR programs which highlight the potential of our GPCR platform to discover drugs for endocrine disorders. Learn more: #drugdiscovery #endocrinology

At Septerna, we are developing an oral therapy for hypoparathyroidism, and we are rapidly advancing this program toward the initiation of clinical trials, because we understand patients are waiting. Learn more about the condition from the @HypoPARAassoc:

June 1st is #WorldHypoparaDay. #Hypoparathyroidism is a rare endocrine disorder driven by absence or inappropriately low levels of parathyroid hormone (PTH). Even on standard-of-care, patients report debilitating physical and cognitive symptoms.

We are pleased to present data from our #GPCR drug discovery engine at #ENDO2024. These results validate our approach & reaffirm our dedication to deliver transformative therapies to patients. Attending ENDO? Join us to learn more:

This month we added five new amazing employees to the team in the areas of Quality Assurance, Facilities, Disease Biology, CMC and DMPK. Welcome to all and we look forward to your contributions!

Over the next month our management team will be present and participate at multiple investor and industry conferences. We look forward to seeing you if you’re attending!

Season's Greetings from Septerna! May your holiday season be merry and bright. #SeasonsGreetings #HappyHolidays

George Xu, Senior Director of Corporate Development & Portfolio Strategy, comments on growing interest #GPCRs & his excitement for the advancements made possible through Septerna's groundbreaking platform. We are doing something quite different here. #drugdiscovery

It’s #ThyroidEyeDisease (TED) Awareness Week, an autoimmune disorder for which treatment options are limited. Septerna is making progress toward a potentially disease-modifying therapy targeting the thyroid stimulating hormone receptor (TSHR), a #GPCR involved in TED.

We are pleased to announce Septerna has been named one of #10StartupsToWatch by @cenmag. It’s an honor to receive this recognition and to be included among such incredible companies doing groundbreaking work: #biotech #innovation.